A Bright Future or Unfulfilled Promise – An Update on Biosimilars and Their Prospects for Contributing to Meaningful Cost Reduction
George Schroeder, M.D. M.S., FACEP.; Seth Whitelaw, J.D., LL.M., S.J.D.; John Murphy, Esq.
Biosimilars have a bright future and promise potentially significant health care cost savings, provided the regulatory, legal and commercial hurdles are removed. Recent activity by CVS and United Healthcare are promising signs that indeed the commercial barriers are starting to come down. However, it remains unclear whether the FDA will help on the regulatory front.